Literature DB >> 26197091

Assessment of planning performance in clinical samples: Reliability and validity of the Tower of London task (TOL-F).

Lena Köstering1, Charlotte S M Schmidt2, Karl Egger3, Florian Amtage4, Jessica Peter5, Stefan Klöppel6, Lena-A Beume7, Markus Hoeren7, Cornelius Weiller7, Christoph P Kaller7.   

Abstract

OBJECTIVE: Executive deficits are frequent sequelae of neurological and psychiatric disorders, but their adequate neuropsychological assessment is still a matter of contention, given that executive tasks draw on a multitude of cognitive processes that are often not sufficiently specified. In line with this, results on psychometric properties of the Tower of London, a task measuring planning ability as a prototypical executive function, are equivocal and furthermore lacking completely for adult clinical populations.
METHODS: We used a structurally balanced item set implemented in the Tower of London (Freiburg version, TOL-F) that accounts for major determinants of problem difficulty beyond the commonly used minimum number of moves to solution. Split-half reliability, internal consistency, and criterion-related concurrent validity of TOL-F accuracy were assessed in patients with stroke (N = 60), Parkinson syndrome (N = 51), and mild cognitive impairment (N = 29), and healthy adults (N = 155).
RESULTS: Across samples, mean split-half and lower-bound indices of reliability of accuracy scores were adequate (r ≥ .7) or higher. Compared to a subset of healthy controls matched for age, sex, and education levels, deficits in planning accuracy emerged for all three clinical samples.
CONCLUSIONS: Based on consistently adequate reliability and a good criterion-related validity of accuracy scores, the TOL-F demonstrates its utility for testing planning ability in clinical samples and healthy adults. Using item sets systematically accounting for several determinants of task difficulty can thus significantly enhance the contended reliability of executive tasks and provide an opportunity to resolve the underspecification of cognitive processes contributing to executive functioning in health and disease.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Executive function; Mild cognitive impairment; Neuropsychological tests; Parkinson disease; Psychometrics; Stroke

Mesh:

Year:  2015        PMID: 26197091     DOI: 10.1016/j.neuropsychologia.2015.07.017

Source DB:  PubMed          Journal:  Neuropsychologia        ISSN: 0028-3932            Impact factor:   3.139


  5 in total

1.  Effects of initial planning on task execution performance of older adults: A naturalistic assessment paradigm.

Authors:  Katelyn D Brown; Maureen Schmitter-Edgecombe
Journal:  J Clin Exp Neuropsychol       Date:  2019-10-28       Impact factor: 2.475

2.  Exploration of gray matter correlates of cognitive training benefit in adolescents with chronic traumatic brain injury.

Authors:  Vander Linden Catharine; Verhelst Helena; Deschepper Ellen; Vingerhoets Guy; Deblaere Karel; Caeyenberghs Karen
Journal:  Neuroimage Clin       Date:  2019-04-16       Impact factor: 4.881

3.  Interaction between cognitive reserve and age moderates effect of lesion load on stroke outcome.

Authors:  Roza M Umarova; Lena V Schumacher; Charlotte S M Schmidt; Markus Martin; Karl Egger; Horst Urbach; Jürgen Hennig; Stefan Klöppel; Christoph P Kaller
Journal:  Sci Rep       Date:  2021-02-24       Impact factor: 4.379

4.  Age as a moderator of the relationship between planning and temporal information processing.

Authors:  Katarzyna Jablonska; Magdalena Stanczyk; Magdalena Piotrowska; Aneta Szymaszek; Barbara Lukomska; Hanna Bednarek; Elzbieta Szelag
Journal:  Sci Rep       Date:  2022-01-28       Impact factor: 4.379

5.  The Effects of Tai Chi on the Executive Functions and Physical Fitness in Middle-Aged Adults with Depression: A Randomized Controlled Trial.

Authors:  Ligong Zhang; Dongshi Wang; Chun Xie; Siwen Liu; Lin Chi; Xuezhi Ma; Fei-Fei Ren
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-13       Impact factor: 2.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.